Palvella Therapeutics (NASDAQ:PVLA) Director Christopher Kiritsy Sells 313 Shares of Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director Christopher Kiritsy sold 313 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total transaction of $49,141.00. Following the completion of the transaction, the director directly owned 250 shares in the company, valued at $39,250. This represents a 55.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Palvella Therapeutics Stock Up 1.1%

Shares of NASDAQ PVLA opened at $157.24 on Friday. The business has a fifty day simple moving average of $148.35 and a 200-day simple moving average of $129.46. The company has a market cap of $2.27 billion, a price-to-earnings ratio of -32.55 and a beta of -0.25. Palvella Therapeutics, Inc. has a 12 month low of $52.36 and a 12 month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.35). As a group, sell-side analysts expect that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PVLA. Group One Trading LLC grew its stake in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares in the last quarter. KBC Group NV bought a new position in Palvella Therapeutics during the first quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. bought a new position in Palvella Therapeutics during the second quarter valued at approximately $35,000. Price T Rowe Associates Inc. MD lifted its stake in Palvella Therapeutics by 11.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock valued at $429,000 after acquiring an additional 433 shares during the last quarter. Finally, Archer Investment Corp acquired a new stake in Palvella Therapeutics in the second quarter valued at approximately $69,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on PVLA shares. Canaccord Genuity Group set a $232.00 target price on Palvella Therapeutics in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $270.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Palvella Therapeutics has a consensus rating of “Buy” and an average price target of $209.14.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.